GlassScriptPhysician profile
Brooke Ludwig
NPI 1134750110
$2,057.56
in general payments reported to CMS, 2019-2025
27 companies · $725 in 2025
The $725 reported for 2025 was more than what 81% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.97 · 2022: $319 · 2023: $517 · 2024: $453 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Education: $60.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.12 |
| Education | $60.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.73 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $266.55 | 2022-2025 | Quviviq, Quviviq |
| Paratek Pharmaceuticals, INC. | $261.12 | 2022-2025 | Nuzyra, Xhance |
| Astellas Pharma US INC | $117.90 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $98.20 | 2024-2025 | Fanapt |
| Lilly USA, LLC | $94.92 | 2022-2024 | Mounjaro, Trulicity |
| Axsome Therapeutics, INC. | $89.80 | 2024-2025 | Auvelity, Symbravo |
| Amgen INC. | $73.34 | 2022-2024 | Otezla, Repatha |
| Organon LLC | $70.45 | 2021-2023 | Nexplanon |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.57 | 2025 | Caplyta |
| Melinta Therapeutics, LLC | $52.02 | 2023-2024 | Kimyrsa, Rezzayo |
| Lucid Diagnostics INC. | $50.56 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $47.92 | 2023-2025 | |
| Novo Nordisk INC | $44.16 | 2023-2025 | Wegovy |
| Inspire Medical Systems, INC. | $28.89 | 2023-2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.64 | 2025 | Spravato |
| Medtronic, INC. | $24.59 | 2025 | Inceptiv |
| Pfizer INC. | $22.52 | 2023 | |
| Merck Sharp & Dohme LLC | $21.46 | 2021 | |
| Phadia US INC. | $19.74 | 2023 | Immunocap |
| Tris Pharma INC | $18.91 | 2025 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $18.60 | 2022 | |
| Corium, LLC | $18.25 | 2025 | Azstarys |
| Merz North America, INC. | $17.46 | 2022 | |
| Boston Scientific Corporation | $16.61 | 2023 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $15.89 | 2023 | Seglentis |
| Ultragenyx Pharmaceutical INC. | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Ludwig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.